A detailed history of China Universal Asset Management Co., Ltd. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 15,863 shares of EDIT stock, worth $43,940. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,863
Previous 9,661 64.2%
Holding current value
$43,940
Previous $45,000 20.0%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$3.39 - $5.96 $21,024 - $36,963
6,202 Added 64.2%
15,863 $54,000
Q2 2024

Jul 19, 2024

SELL
$4.67 - $7.28 $28,262 - $44,058
-6,052 Reduced 38.52%
9,661 $45,000
Q1 2024

Apr 29, 2024

BUY
$7.03 - $11.07 $44,028 - $69,331
6,263 Added 66.28%
15,713 $117,000
Q4 2023

May 21, 2024

SELL
$6.25 - $11.11 $39,143 - $69,581
-6,263 Reduced 39.86%
9,450 $95,000
Q4 2023

Jan 23, 2024

BUY
$6.25 - $11.11 $45,968 - $81,714
7,355 Added 351.07%
9,450 $96,000
Q3 2023

May 21, 2024

BUY
$6.92 - $9.31 $8,234 - $11,078
1,190 Added 131.49%
2,095 $16,000
Q3 2023

Oct 30, 2023

BUY
$6.92 - $9.31 $8,234 - $11,078
1,190 Added 131.49%
2,095 $16,000
Q2 2023

May 21, 2024

SELL
$6.36 - $11.47 $190 - $344
-30 Reduced 3.21%
905 $7,000
Q2 2023

Jul 27, 2023

SELL
$6.36 - $11.47 $190 - $344
-30 Reduced 3.21%
905 $7,000
Q1 2023

May 21, 2024

BUY
$7.03 - $11.53 $1,666 - $2,732
237 Added 33.95%
935 $6,000
Q1 2023

Apr 27, 2023

BUY
$7.03 - $11.53 $1,666 - $2,732
237 Added 33.95%
935 $7,000
Q4 2022

May 21, 2024

SELL
$8.32 - $13.21 $124,924 - $198,348
-15,015 Reduced 95.56%
698 $6,000
Q4 2022

Jan 31, 2023

BUY
$8.32 - $13.21 $449 - $713
54 Added 8.39%
698 $6,000
Q3 2022

Oct 21, 2022

BUY
$12.16 - $19.42 $7,831 - $12,506
644 New
644 $8,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $190M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.